Go to contentGo to menuGo to search

OPTOPATH

A Rodent Platform Entirely Dedicated to Innovation in Experimental Psychopathology

The June 3, 2014

OptoPath constitutes a major and decisive technological leap for the identification of new therapeutic targets against 4 major psychological disorders: Addiction, Obesity, Anxiety-related disorders and Memory deficits.

 The OPTOPATH website.....

OptoPath combines the expertise of neurobiologists, electrophysiologists and experimental psychologists.Their efforts are directed towards:
Innovative rodent behavioral models of these highly incident psychopathologies with complex behavioral disturbances. To be as close as possible from the human symptomatology, the diagnosis criteria and clinical characteristics of the pathologies of interest have been operationalized into rodents.
Cutting edge tools for neurobiological investigations coupling technologies such as multi-sites electrophysiology, optogenetics and deep brain vascular imaging.

Challenges
Four main obstacles currently hinder our ability to identify relevant underlying neurobiological alterations:
The absence of animal models able to reproduce the complexity of the symptoms of these psychopathologies
The lack of adapted technological tools to appropriately investigate the underlying neurobiological mechanisms of these behavioral pathologies
The unavailability of sufficient material resources
The lack of federation of human expertise, which is necessary to a transnosographic study of pathologies that share common dimensions
Strategy
Creating and coupling Cutting edge tools for in vivo brain activity recording and manipulation
Developing new high face validity behavioural models of psychopathologies.
Faculty
OptoPath involves 14 scientists from 9 research teams from two research institutes. It therefore concentrates a large number of technical and methodological competences that span all major neurobiological levels (molecules, cells, integrated brain circuits, behaviors)
Resources
Optopath is a project granted in the context of the IA (Investissements d’Avenir – Investment for the future plan of the French government). Precisely, Optopath is an Equipex project. It was granted 6 000 000 euros over 9 years.

 

 

More...


An interview with Véronique Deroche Gamonet the technological platform leader.


You are interested by a truly collaborative approach to develop new therapies or diagnostic tests against addiction, obesity, memory deficits or anxiety?

Please contact us:
Plateforme OptoPath
Neurocentre Magendie
146 rue Léo Saignat
33077 Bordeaux
France
optopath@u-bordeaux.fr



Optopath publications...


Prefrontal parvalbumin interneurons shape neuronal activity to drive fear expression

Courtin J, Chaudun F, Rozeske RR, Karalis N, Gonzalez-Campo C, Wurtz H, Abdi A, Baufreton J, Bienvenu TC, Herry C. . Nature (2014) 505(7481):92-6.

 

Administration Influences Drug Seeking in the Rat: Optogenetic Evidence for a Role of the Prelimbic Cortex
Martín-García E, Courtin J, Renault P, Fiancette JF, Wurtz H, Simonnet A, Levet F, Herry C, Deroche-Gamonet V. Frequency of Cocaine Self-Administration Influences Drug Seeking in the Rat: Optogenetic Evidence for a Role of the Prelimbic Cortex. Neuropsychopharmacology. 2014 Mar 17. doi: 10.1038/npp.2014.66. [Epub ahead of print]